Clinical data | |
---|---|
Pronunciation | /proʊˈkeɪnəmaɪd/ |
Trade names | Pronestyl, Procan, Procanbid, others |
AHFS/Drugs.com | Monograph |
Routes of administration | IV, IM, by mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 85% (by mouth) |
Protein binding | 15 to 20% |
Metabolism | Liver (CYP2D6-mediated) |
Elimination half-life | ~2.5 to 4.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.072 |
Chemical and physical data | |
Formula | C13H21N3O |
Molar mass | 235.331 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia. In addition to blocking the INa current, it inhibits the IKr rectifier K+ current.[1] Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.[2]